Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Shareholder Meeting (May 2013)
17 slides from Fresenius Medical Care's shareholder meeting presentation, May 16, 2013
Slide 1: Annual General Meeting 2013 Welcome
Annual General Meeting 2013 Welcome Rice Powell Chief Executive Officer and Chairman of the Management Board Frankfurt | May 16, 2013
Slide 2: 2012 A record year
2012 A record year FY 2012 Growth in $ millions Net revenue 13,800 +10% Net income 1,187 +11% Net income, adjusted for special items 1,118 + 4% Operating cash flow 2,039 +41% Achieved targets for 2012 Strong growth in Dialysis Services as well as Dialysis Products Expanded our global market sh
Slide 3: Strong growth across the group in each region
Strong growth across the group in each region North America International Revenue $ 9,031 m +14% Revenue $ 4,740 m + 9%cc Organic growth + 4% Organic growth + 6% Europe $ 2,893 m + 6%cc Asia-Pacific $ 1,043 m + 7%cc Latin America $ 804 m +24%cc 4 3 1 North America 65% 2 13,800 2 Europe/Middle East/A
Slide 4: Dialysis Services – Global market leader
Dialysis Services – Global market leader Patients 2012 Treatments 2012 Clinics 2012 in millions Total 257,916 38.6 3,160 Growth + 11% + 12% + 9% North America 164,554 24.4 2,082 Growth +16% +13% +13% International 93,362 14.2 1,078 Growth + 3% + 11% + 2% We are the leading dialysis provider in eac
Slide 5: Dialysis Products – Leader in every major product group
Dialysis Products – Leader in every major product group Rank 1 Rank 2 Dialyzers FME Gambro Dialysis machines FME Gambro Hemodialysis concentrates FME Fuso Bloodlines FME Gambro Peritoneal dialysis products Baxter FME Dialyzers Dialysis machines FME FME 45% 55% ~100,000,000 dialyzers Competitors Comp
Slide 6: We added 7,000 jobs globally
We added 7,000 jobs globally 4 3 1 North America 59% ~86,150 2 Europe/Middle East/Africa 24% Employees (FTE) 2 3 Asia-Pacific 7% +9% 1 4 Latin America 10% More than doubled the number of employees over the last 10 years (2003: ~41,100) Dialysis Services ~77% and Dialysis Products ~23% © | Annual
Slide 7: Decade of impressive growth
Decade of impressive growth Revenue in $ millions Net income in $ millions 11% CAGR 2003–2012 15% CAGR 2003–2012 13,800 1,187 +150% +259% 5,528 331 2003 2012 2003 2012 CAGR = Compounded Annual Growth Rate © | Annual General Meeting | 2013 7
Slide 8: Delivering long-term value
Delivering long-term value Total Return 2003 to 2012 – Average annual performance Fresenius Medical Care in € 16% DAX-Index* 11% DJ Eurostoxx 5% Healthcare-Index 0% 4% 8% 12% 16% 20% * no dividends or coupons © | Annual General Meeting | 2013 8
Slide 9: 2012 16th consecutive dividend increase and change of mid-term dividend policy
2012 16th consecutive dividend increase and change of mid-term dividend policy Dividend per ordinary share in € +9% 0.75 2012 net income growth Compounded 0.69 annual growth of 11% rate 10% We will revise our mid-term dividend policy Current: dividend per share growing at approx. 50% of the gr
Slide 10: Topic 6 of today's agenda
Topic 6 of today‘s agenda Preference shares 3,973,333 Ordinary shares 306,713,091 Ordinary shares 302,739,758 As of 31.12.2012 Pro Forma © | Annual General Meeting | 2013 10
Slide 11: 2013 Outlook
2013 Outlook In $ millions 2012 2013 E Growth Reported Revenue 13,800 > 14,600 > 6% EBIT 2,219 2,300-2,500 4-13% Net income 1,187 Investment gain -140 Net income 1,047 1,100-1,200 5-15% adjusted for investment gain © | Annual General Meeting | 2013 11
Slide 12: Expected development of global dialysis patient population
Expected development of global dialysis patient population Expected patient growth of around 6% Driven by age, lifestyle and higher life expectancy Number of dialysis patients worldwide – Forecast to 20201 in millions 4 Dialysis patients in 2020: ~3.8 millions 3 2 1 0 1970 1975 1980 1985 1990 19
Slide 13: Market opportunities for Fresenius Medical Care
Market opportunities for Fresenius Medical Care Revenue Entering into Phase III in $ billions Continued 20 Expansion of 18 Dialysis Products & Services 16 Phase II 13.8 + 14 Additional Services Geographic 12 Expansion of Vascular Access Dialysis Products 10 & Services Phase I 8 Oral Pharmaceuticals
Slide 14: Growth strategy to ensure continued success
Growth strategy to ensure continued success Leader in growing market – Dialysis market growing 4%cc and estimated to reach $ 100 billion by 2020 – Patient growth driven by age, life style and mortality reduction Provide highest standard of patient care Deliver shareholder value – Vertical integr
Slide 15: Fresenius Medical Care. The Renal Company. A Lifelong Commitment.
FRESENIUS MEDICAL CARE. THE RENAL COMPANY. A LIFELONG COMITTMENT. Thank you very much for your attention, your continued interest and your support! © | Annual General Meeting | 2013 15
Slide 16: Annual General Meeting 2013
Annual General Meeting 2013 Rice Powell Chief Executive Officer and Chairman of the Management Board Frankfurt | May 16, 2013
Slide 17: Safe Harbor Statement
Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on its views w
Fresenius Medical Care — Shareholder Meeting (May 2013) on 6ix